Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation

Canadian Journal of Cardiology

Volumn 13, Issue 5, 1997, Pages 469-478

  Carrier, Michel ^a,b   White, Michel ^a   Pellerin, Michel ^a   Pelletier, Guy B ^a   Pelletier, L Conrad ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE   (Canada)

Author keywords

Cyclosporine; Induction of immunosuppression; Oral formulation

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; RISK; URINE VOLUME;

ADMINISTRATION, ORAL; COHORT STUDIES; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0030912896     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable transplant recipients. Transplant Proc 1994;26:2940-3.
2. Frei U, Taesch S, Niese D. Use of Sandimmune Neoral in renal transplant patients. Transplant Proc 1994;26:2928-31.
3. Belli LS, Slim OA, De Carlis L, et al. Neoral in liver transplant patients: Pharmacokinetic study and clinical implications. Transplant Proc 1994;26:2981-2.
4. Carrier M, Pelletier GB, Cartier R, Leclerc Y, Robitaille D, Pelletier LC. Induction of immunosuppression with rabbit antithymocyte globulin: Five-year experience in cardiac transplantation. Can J Cardiol 1993;9:171-6.
5. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Transplant 1990;9:587-93.
6. Ferraro P, Carrier M, White M, Pelletier GB, Pelletier LC. Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection. Ann Thorac Surg 1995;60:372-6.
7. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986;314:1219-25.
8. Copeland JG, Emery RW, Levinson NM, et al. Cyclosporine: An immunosuppressive panacea? J Thorac Cardiovasc Surg 1986;91:26-39.
9. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995;59:505-11.
10. Mikhail G, Eadon H, Leaver N, Yacoub M. Use of Neoral in heart transplant recipients. Transplant Proc 1994;26:2985-7.
11. Fiocchi R, Mamprin F, Gamba A, et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994;26:2994-5.
12. Copeland JG, Icenogle TB, Williams RJ, et al. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation. J Thorac Cardiovasc Surg 1990;99:852-60.
13. Carrier M, Jenicek M, Pelletier LC. Value of monoclonal antibody OKT3 in solid organ transplantation: A meta-analysis. Transplant Proc 1992;24:2586-91.
14. Pritzker MR, Lake KD, Reutzel TJ, et al Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. J Heart Lung Transplant 1992:11:415-20.
15. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
16. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994;57:848-51.
17. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection. Transplantation 1996;61:722-9.
18. Bocher WO, Schirmacher P, Lohr HF, et al. Hepatic manifestation of hemolytic uremic syndrome in an allogeneic bone marrow transplant recipient. Gastroenterology 1995;33:543-5.